Scientific Advisory Board Contact News Investors Press Releases Nov. 29, 2021 Bioasis Announces Annual General Meeting Details NEW HAVEN, Conn., Nov. 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain… Read more » Oct. 28, 2021 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021 NEW HAVEN, Conn., Oct. 28, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more » Sep. 30, 2021 Bioasis to Attend Upcoming Industry Conferences NEW HAVEN, Conn., Sept. 30, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain… Read more » Aug. 18, 2021 Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor NEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more » Aug. 9, 2021 Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology to enhance the delivery of biologics across the blood-brain barrier (“BBB”) for the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more » Jul. 29, 2021 Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A NEW HAVEN, Conn., July 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3TM?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced… Read more » Jul. 20, 2021 Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager NEW HAVEN, Conn., July 20, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more » Jul. 7, 2021 Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis NEW HAVEN, Conn., July 07, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology to enhance the delivery of biologics across the blood-brain barrier (“BBB”) for the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more » Jul. 1, 2021 Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer NEW HAVEN, Conn., July 01, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more » Jun. 30, 2021 Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration NEW HAVEN, Conn. and MANCHESTER, United Kingdom, June 30, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) (“Bioasis”) and Oxyrane UK Ltd. (“Oxyrane”) are pleased to announce the initiation of a research collaboration. Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier… Read more » 1 2 3 4 5 6 7 Categories Corporate (83) Events & Presentations (20) Financial (69) Product (41) Contact Deborah Rathjen deborah@bioasis.us Graeme Dick graeme@colwellcapital.com Subscribe Email Address * First Name Last Name Contact Policies © 2021 Bioasis Technologies, Inc.